NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option to extend to two, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. While Compugen would not disclose financial details of the arrangement, a company spokesperson revealed that it was in the “multi-million dollar per year” range.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.